Clinical Trials Logo

Uveal Melanoma clinical trials

View clinical trials related to Uveal Melanoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05482074 Withdrawn - Uveal Melanoma Clinical Trials

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Start date: October 4, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy. -The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

NCT ID: NCT04184518 Withdrawn - Metastatic Cancer Clinical Trials

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

CEDUVEAL-M
Start date: May 2020
Phase: Phase 2
Study type: Interventional

Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.

NCT ID: NCT03022565 Withdrawn - Uveal Melanoma Clinical Trials

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

Start date: January 2020
Phase: Early Phase 1
Study type: Interventional

This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.